dN/dS dynamics quantify tumour immunogenicity and 1 predict response to immunotherapy 2 3 Luis Zapata^{1*}, Giulio Caravagna¹, Marc J Williams², Eszter Lakatos², 4 Khalid AbdulJabbar¹, Benjamin Werner¹, Trevor A Graham^{2*}, Andrea 5 Sottoriva^{1*} 6 7 8 ¹ Centre for Evolution and Cancer, Institute of Cancer Research, London, UK ² Centre for Genomics and Computational Biology, Barts Cancer Institute, Barts 9 10 and the London School of Medicine and Dentistry, Queen Mary University of London, UK 11 12 Correspondence to: luis.zapata@icr.ac.uk, t.graham@gmul.ac.uk and 13 andrea.sottoriva@icr.ac.uk 14 15 Abstract 16 17 Immunoediting is a major force during cancer evolution that selects for clones with low immunogenicity (adaptation), or clones with mechanisms of immune 18 evasion (escape). However, quantifying immunogenicity in the cancer genome 19 and how the tumour-immune coevolutionary dynamics impact patient outcomes 20 21 remain unexplored. Here we show that the ratio of nonsynonymous to synonymous mutations (dN/dS) in the immunopeptidome quantifies tumor 22 23 immunogenicity and differentiates between adaptation and escape. We analysed 8.543 primary tumors from TCGA and validated immune dN/dS as a measure of 24 25 selection associated with immune infiltration in immune-adapted tumours. In a cohort of 308 metastatic patients that received immunotherapy, pre-treatment 26 lesions in non-responders showed increased immune selection (dN/dS<1), 27 28 whereas responders did not and instead harboured a higher proportion of genetic 29 escape mechanisms. Ultimately, these findings highlight the potential of 30 evolutionary genomic measures to predict clinical response to immunotherapy. 31

- 32
- 33

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.21.215038; this version posted July 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

34 Introduction

35

Cancer is an evolutionary process, where natural selection acts upon somatic 36 mutations that alter phenotypes, and drives adaptation^{1,2}. Recent advances in 37 38 genomic technologies have enabled the characterisation of mutational landscapes in thousands of malignant^{3,4}, and healthy somatic tissues^{5,6,7,8}. These 39 studies found that a) 2 to 5 driver mutations are sufficient to initiate a malignancy. 40 b) driver mutations are also present in normal tissue^{5,6,7}, c) 90-95%% of somatic 41 point mutations are neutral^{7–9}, and d) the signals of negative selection in somatic 42 tissues are weaker compared to germline evolution^{7,10}. However, the roles of 43 negative, positive, and neutral evolution during carcinogenesis remains 44 debated¹¹, especially with regards to the extent of neutral evolution¹²⁻¹⁴ and 45 46 negative selection^{7,8,15,16}.

47

The application of evolutionary theory allows us to infer cell growth dynamics, the 48 number of driver alterations^{17,18} and their selective fitness coefficients^{19–22}, as well 49 50 the impact of deleterious mutations during cancer progression^{23,24}. An as evolutionary metric recently used to detect selection in cancer studies is the ratio 51 of nonsynonymous to synonymous mutations, $dN/dS^{7,8,25-27}$. The rationale is that 52 within a genomic locus, nonsynonymous mutations that decrease cell fitness will 53 54 show a paucity (negative selection, dN/dS < 1) while nonsynonymous mutations that increase cell fitness will be more frequent (positive selection, dN/dS > 1) 55 compared to synonymous neutral mutations. Mutations modulate fitness by 56 altering the birth-death rate of a cell (driver and deleterious mutations) or by 57 causing immune-mediated predation of the lineage (neoantigens or immunogenic 58 mutations). We recently explored the evolutionary dynamics caused by negative 59 selection operating in cancer, demonstrating that negative selection - and its 60 release by immune escape - leads to a predictable neoantigen variant allele 61 frequency (VAF) distribution²⁸. In theory, the shape of the neoantigen VAF 62 63 distribution can measure selection, but technical limitations around neoantigen detectability in standard genome sequencing make the method impractical and 64 under-powered. Here we show how dN/dS-based measures offer a robust 65

66 means to quantify negative selection strength and detect competing selective67 forces acting in distinct regions of the cancer genome.

68

The notion that the immune system influences cancer progression originated in 69 70 the early 1900s^{29,30}. It was only a century later, that studies in mice demonstrated 71 that genetically inbred mice lacking lymphocytes, developed more spontaneous 72 and chemically induced tumors than their wild-type counterparts^{30–32}. These 73 results engendered the concept of cancer immunoediting where tumor cells are 74 subject to three phases: elimination, equilibrium, and escape²⁹. Cancer 75 immunoediting is an evolutionary process that shapes tumour immunogenicity by selecting for clones depleted of neoantigens (immune-adapted) or with an 76 immune evasion phenotype (immune-escaped)^{33–35}. Neoantigens are generated, 77 78 among other mechanisms, by single nucleotide variants (SNVs) leading to 79 aminoacidic changes in a peptide previously recognized as a self-antigen³⁶. 80 However, the extent of immunogenicity derived from SNVs in self-antigens 81 remains unclear, particularly if anchor positions of the wild-type peptide are 82 affected³⁷. In our previous work, we observed signals of immune-mediated 83 negative selection in the immunopeptidome, defined as all natively MHC-bound genomic regions, associated to levels of immune infiltration. Nonetheless, a 84 recent study claimed that after applying a more stringent normalization method 85 these regions do not harbour signals of selection¹⁶. In this work, we corroborated 86 87 our earlier findings and we further provide an alternative explanation for the lack of signal reported recently. 88

89

The recent discovery of immune checkpoints (e.g. PD1 or CTLA4) as mechanism 90 91 of immune evasion, led to the development of cancer therapies using immune 92 checkpoint inhibitors (ICIs). Despite the promising clinical results of ICIs, only 93 30% of patients treated with these therapies show significant response. Therefore, considerable effort has been dedicated to understand the interaction 94 95 between the immune system and cancer^{38–43}, and to identify genetic determinants of immunotherapeutic response. To date, quantification of tumor 96 mutation burden (TMB) is the primary genomic biomarker for enrolling patients 97

into ICI treatment. The underlying hypothesis for TMB as a biomarker is that a
higher number of somatic mutations leads to a higher number of neoantigens,
and therefore a higher likelihood of immune clearance after checkpoint inhibition.
However, recent studies have shown that even mismatch repair proficient tumors
display a pathological response⁴⁴, emphasizing the need for quantifying the true
immunogenicity of the cancer genome and their potential clinical response to
immunotherapy.

105

106 Here, we modelled cancer initiation and progression by adapting a stochastic 107 branching process⁴⁵ to simulate changes in dN/dS over time as a measure of selection and tumor immunogenicity during immunoediting. Using the insight 108 109 gained from our model, we assessed dN/dS values in 8543 primary tumours, as 110 well as 308 metastatic cancers treated with ICIs. We first corroborate that immune 111 dN/dS correlates with levels of tumor infiltrating lymphocytes – a measure of the strength of immunoediting - in non-escaped tumors. Finally, by estimating 112 113 immune dN/dS in pre-treated patients, we reported clinical response in immune-114 escaped patients that had an absence of immune selection (immune $dN/dS \sim 1$). In contrast, tumors with low immune dN/dS, and therefore low levels of tumor 115 116 immunogenicity, did not respond to the action of immune checkpoint inhibitors.

117


118 Results

119 A mathematical model of immunoediting

120 We extended our previous modelling work to incorporate the acquisition of 121 nonsynonymous and synonymous mutations in driver (positively selected) and passenger (neutral) loci^{24,46,47}, as well as in regions exposed to the immune 122 123 system and regions that confer immune-evasion properties (Fig 1). The 124 interaction of different mutations and the observed evolutionary dynamics can be 125 simplified into four phases: 1) A pre-neoplastic phase where cells do not have cancer driver mutations but may acquire passenger, immunogenic or escape 126 127 mutations (Fig 1A), 2) a neoplastic phase that begins when a driver mutation avoids stochastic drift and initiate a clonal expansion (Fig 1B), 3) an elimination 128 phase where cells acquiring somatic mutations recognized by the immune 129

130 system are eliminated (Fig 1C), and 4) a phase where expanding clones lead to a clinically-detectable tumor through either depletion of immunogenic mutations 131 (immune adapted) or through a mutation in the genome that triggers an immune 132 escape mechanism (immune escaped) (Fig 1D). An activated escape mechanism 133 134 hides the clone from the immune system so that neoantigens accrue without 135 being depleted by negative selection raising the overall tumor immunogenicity (Fig S1A). It is possible for these phases to overlap each other. For example, an 136 escape mutation occurring pre-driver acquisition and thus pre-clonal expansion 137 138 leads to tumors "born" immune-escaped.







141Figure 1. Description of the stochastic branching process used to model immunoediting. A) An initial set of142wild type cells (Pre-malignant cell) divide and accumulates mutations. B) A driver mutation increases the143probability of cell division initiating a phase of increased proliferation of clones (Cancer cell). C) During the144phase of immune attack, the immune system removes cells carrying immunogenic mutations and might145eradicate the tumor completely or force the tumor to adapt or escape. D) Two possible scenarios emerge146as the outcome of immunoediting, cancer cells survive not harbouring immunogenic mutations (Immune147adapted) or due to the acquisition of an immune evasion mechanism (Immune escaped). E) These scenarios

can be differentiated by looking at the ratio of nonsynonymous to synonymous mutations (dN/dS) in immune
exposed regions of the genome. We defined two hypotheses of immune recognition: F) Single cell immune
attack where any single cell carrying a neoantigen is able to initiate an immune response and be eliminated
at a rate of immune-mediated cell death of PIS, G) Clonal immune attack where a minimum percentage of
immunogenic cells is needed to elicit an immune response, as recently observed in mice models⁴⁸.

153

We initiated our model in the pre-neoplastic phase with a pool of N cells having 154 155 an equal probability of birth (b) and death (d): b=d=0.5 (Methods). For each 156 successful cell division, a number of new mutations are sampled from a Poisson 157 distribution with mean $\mu \times L$ (mutation rate measured in mutations per base pair 158 per cell division multiplied by the length of the coding genome, L). We introduced 159 nonsynonymous and synonymous mutations at a constant relative rate of 3 to 1 given the expected genome composition⁴⁹, so we could calculate the ratio 160 161 between these two types of mutations (dN/dS) in the evolved population of 162 tumour cells. We assumed that passenger nonsynonymous and all synonymous mutations are neutral. Once a cell acquired a nonsynonymous mutation in a 163 driver, the probability of cell division *b* increases by a fixed value obtained from a 164 Gompertz function (Methods), driving the next stage of tumorigenesis. 165

166

167 During immunoediting^{29,50}, cells carrying an immunogenic mutations may elicit an 168 immune response. We tested whether or not dN/dS values derived from the 169 immunopeptidome, the portion of the genome constantly exposed to immune 170 recognition (defined as 'Immune dN/dS'), quantifies overall tumor 171 immunogenicity, and differentiates between adaptation and escape. We 172 expected that when the immune predation was active and there were no escape mechanisms evolved, the immune dN/dS would be lower than 1 showing overall 173 174 low tumor immunogenicity. Conversely, in the presence of escape mechanisms 175 immune dN/dS would have values closer to 1, and therefore high 176 immunogenicity. Additionally, we could also measure a 'global dN/dS' by using mutations in all loci of the genome, and a 'driver dN/dS' by considering only 177 mutations in driver loci (Fig 1E). We then modelled two hypotheses of immune 178 179 recognition (Fig S1B): (1) a classic model (model A) where a single cell carrying 180 an immunogenic mutation is sufficient to elicit an immune response (Fig. 1F), and (2) a clonal model (model B), recently suggested⁴⁸, where a percentage 181

182 *Pclonesize* of the total cells carrying the same immunogenic mutation is needed for the immune system to attack (Fig. 1G). In model A, the immune system is 183 constantly pruning immunogenic cells, whereas model B produces a "rise and 184 fall" pattern where immunogenic cells are allowed to expand to a threshold size 185 186 but are then eliminated, similar to mass extinction events. Cells bearing a 187 neoantigen are killed at an immune-mediated cell death rate P_{IS} , where $P_{IS} \in$ 188 [0,1]. This parameter models the stochastic probability of encounters between 189 antigen presenting cells and cytotoxic T-cells. Model parameters are summarized 190 in Supplementary Table 1.

191

Evolutionary dynamics of *dN/dS* during immunoediting reveals genomic signals of tumor immunogenicity


194

To first understand dN/dS dynamics during the pre-neoplastic phase, we 195 simulated the acquisition of neutral mutations only (non-synonymous passenger 196 197 and synonymous mutations) in an initial population of 32 cells for 30 generations 198 (Fig S2). We compared three mutation rate regimes similar to those founds in 199 some neoplasms: microsatellite stable ($\mu MSS = 10^{-8}$ mutations/bp/division), 200 microsatellite unstable (μ MSI=10⁻⁷), and POLE-like (POLE=10⁻⁶). On average, the population size remained constant over time for the three regimes and the 201 202 number of mutations was higher for higher mutation rate regimes (Fig S2A-B). The average number of mutations per simulated population was 10², 10³, and 10⁴ 203 204 for each mutation rate regime respectively (Fig S2B). As expected under neutral 205 dynamics, we observed that the average dN/dS did not deviate significantly from 206 1 and the variance was lower at high mutation rates. (95%CI for 10^{-8} : 0.54-2.31, 207 MSI:0.79-1.30, POLE:0.91-1.06) (Fig S2C).

208

To determine the influence of positive selection on *dN/dS* values over time during the increased proliferation phase, we simulated only passenger and driver events. We simulated 1000 datasets assuming 0.1%, 0.5% and 1% of driver sites (Fig S3). We focused our analysis on simulations where a clonal expansion occurred, as defined by a growing population of more than 1000 cells within 100

generations (Fig 2A). We calculated dN/dS over time for all mutations (global 214 dN/dS) and for only driver mutations (driver dN/dS). We observed large 215 216 fluctuations of the global dN/dS values among the first generations due to the low 217 number of mutations (Fig S3D). Interestingly, the accumulation of neutral variants pushed global dN/dS values to 1. Driver dN/dS peaked at high values and 218 subsequently decreased towards one due to the accumulation of low frequency 219 220 neutral variants (Fig S3E). As we demonstrated in Williams et al²¹, mutation frequency and driver dN/dS are expected to be positively associated showing the 221 222 highest values at the largest clone sizes (Fig 2B). Accordingly, and as observed 223 recently in clonal hematopoiesis²², the allele frequency spectrum (Cancer Cell 224 fraction or CCF) of synonymous and non-synonymous mutations (Fig. 2C) showed that the observed high driver dN/dS is a consequence of proportionally 225 226 fewer synonymous mutations at higher CCF thresholds compared to 227 nonsynonymous mutations.



228

229 Figure 2. Immunoediting leads to tumor adaptation or escape. A) We defined two outcomes for each 230 simulation: expansion and extinction. Expansion: Clonally expanded populations (Blue) that reached an 231 upper limit of number of cells in the first n generations. Extinction: Simulations that drifted to extinction among 232 the first n generations (Orange). B) driver dN/dS relationship to the cancer cell fraction. As described in 233 Williams et a^{l^2} we show in our model that driver dN/dS increases at increasing values of clonality. C) 234 235 Relative proportion of nonsynonymous to synonymous mutations. The upward trend of dN/dS is due to a high proportion of synonymous mutations removed at increasing CCF cut-offs. D). Immune dN/dS 236 relationship to cancer cell fraction for single cell (model A, Red) and for the clonal model (model B, Blue). A 237 sharp decrease in dN/dS at increasing CCF cut-offs consistent with the theoretical predictions for strong 238 negative selection²¹. E) Immune dN/dS relationship to the probability of immune-mediated cell death at 239 different levels of CCF. At low CCF, the dN/dS for model B is closer to one across all levels of immune death 240 due to the presence of several undetected small frequency clones carrying neoantigens. At high CCF, both 241 models show strong association between immune death and dN/dS. This results into cancer clones depleted 242 of neoantigens, classified as immune-adapted and bearing an overall low tumor immunogenicity. F) Immune 243 dN/dS at different CCF cut-offs when including escape mutations at 1% rate. At low CCF levels, immune 244 dN/dS decreases when increasing CCF but escaped clones push the signal of immune dN/dS towards one 245 at high CCF cut-offs for model B. G) Immune dN/dS relationship to the probability of immune-mediated cell 246 death at different levels of CCF when escape mutations are included. For both models, increasing the 247 probability of escape events pushes dN/dS values back to one for all CCF cut-offs, reflecting a relaxation of immune-mediated negative selection. Ultimately, these tumors are growing with escape mechanisms that
 allow the accumulation of neoantigens that increase the overall tumor immunogenicity.

250

251 During the elimination phase, in addition to driver and passenger mutations, we 252 introduced immunogenic mutations (5% of immunogenic sites) and explored the dynamics under two mechanisms of immune recognition (Single cell versus 253 254 clonal immune attack). We first calculated immune dN/dS values at different 255 cancer cell fraction (CCF) cutoffs. We observed that at increasing clone sizes the 256 immune dN/dS, and therefore tumor immunogenicity, value was approaching 257 zero for both models (Fig 2D). As in model B negative selection is absent for 258 small clones (low CCF), immune dN/dS was closer to 1. Then, we calculated 259 immune dN/dS at varying rates of immune-mediated cell death, P_{IS}, for different 260 clone sizes (Fig 2E). We first confirmed that when the immune system was 261 inactive ($P_{IS} = 0$), the immune dN/dS was one for all clones. At increasing levels 262 of effective immune surveillance both models demonstrated depletion of 263 immunogenic mutations, and therefore low levels of tumor immunogenicity. 264 Immune *dN/dS* in model B was less affected by this parameter given that multiple 265 immunogenic mutations can remain hidden at low frequency. Ultimately, these 266 simulations showed how immune dN/dS reveals the action of immune-mediated 267 negative selection and can be used as a proxy for tumor immunogenicity.

268

269 We next explored immune dN/dS values during the evolution of immune escape. 270 The activation of escape is modelled as a stochastic event occurring at a fixed 271 rate that depends on the proportion of escape sites in the genome. We repeated 272 simulations using an immune-mediated cell death of $P_{IS} = 1$ at different rates of 273 escape. We first found that when the proportion of escape sites was 1%, immune 274 dN/dS captured the action of immune-mediated negative selection across the 275 whole frequency spectrum (Fig 2F). In model B, immune escape pushed immune 276 dN/dS values back to one, slightly increasing overall tumor immunogenicity. At 277 higher rates of immune escape, we observed increased immune dN/dSdemonstrating how tumor immunogenicity is restored for all clone sizes when 278 escape events are more common (Fig 2G). Notably, when the escape rate was 279 280 5%, all clone sizes in model B reached immune dN/dS values close to one,

highlighting high levels of tumor immunogenicity. By acquiring escape mechanisms, negative selection in the immunopeptidome is relaxed, the accumulation of immunogenic mutations becomes neutral, and tumor immunogenicity is restored.

285


The results of our modelling provide a theoretical framework of co-evolution of 286 287 somatic cells and the immune system and a basis to quantify tumor 288 immunogenicity based on immune dN/dS. Further, it illustrates the importance of 289 choosing an appropriate region of the genome to analyse immune selection and 290 how clone sizes explain different levels of tumor immunogenicity. Moreover, we 291 speculate that when mixing patients that are immune-escaped with non-escaped, 292 signals of immune-mediated negative selection are no longer representative of 293 the overall tumor immunogenicity.

294

High levels of lymphocyte infiltration are associated to strong immunemediated negative selection and low levels of tumor immunogenicity

297 To measure global, driver, and immune dN/dS values using genomic data, we developed SOPRANO (Selection On PRotein ANOtated regions), a bioinformatic 298 299 pipeline that measures the extent of selection in specific regions of the genome 300 (github.com/luisgls/SOPRANO). It extends our previous work, where we 301 calculated dN/dS corrected for mutational context using a 7-substitution type (SSB7) or a 192-substitution model (SSB192)⁸. Here, we have extended the 302 303 method to account for any set of concatenated genomic regions allowing for patient- and region- specific dN/dS estimates. We applied SOPRANO to 8543 304 tumour samples from 19 cancer types from The Cancer Genome Atlas (TCGA), 305 using the SSB192 model (Fig 3, Supplementary Table 2). We compared the ratio 306 307 of dN/dS values between regions inside and outside the immunopeptidome 308 (ON/OFF dN/dS). We defined the immunopeptidome as all possible wild-type 9mer regions present in the genome of a patient that are predicted to bind to the 309 310 MHC-I complex with an affinity of %rank < 0.5 as defined in netMHC4.0 (Fig S4). In our first analysis, we used our previously published set of regions that bind to 311 HLA-A0201 and compared them to a recently published proto-HLA¹⁶ consisting 312

of multiple HLA alleles. We found that lung adenocarcinoma (LUAD) and 313 melanoma (SKCM) showed a depletion of nonsynonymous mutations in HLA-314 A0201 binding regions, and that LUAD, HSNC and LUSC showed a depletion of 315 nonsynonymous mutations in proto-HLA regions (Fig 3A). We compared the 316 317 immune dN/dS values (ON/OFF dN/dS) obtained using SOPRANO to the values of immune selection (normalized HLA-binding mutation ratio or HBMR), recently 318 reported by Van Den Eynden et al¹⁶. We observed a significant correlation 319 between the ON/OFF *dN/dS* ratio and the reported normalized HBMR using the 320 321 proto-HLA (R=0.77, P Value= 0.00054, Fig 3B) but not when comparing to the 322 HLA-A0201 (R=0.37, P Value= 0.15, Fig S5). Expectedly, the correlation for the 323 HLA-A0201 was lower given the HBMR value was calculated using multiple HLAs- binding regions and therefore every patient not carrying the proto-HLA 324 325 allele will contribute with only neutrally accumulating mutations. In consequence, 326 it is important to note that the smaller the fraction of the assessed region that is 327 truly under immune selection, the more neutral the dN/dS value would appear. 328



329

330 Figure 3. Immune dN/dS and immune activity across multiple tumor types. A) Immune dN/dS (ON/OFF dN/dS 331 ratio) in multiple tumor types using either a curated HLA-A0201 target region or a proto-HLA consisting of 332 the most common HLA haplotypes in the population obtained from Van Den Eynden et al¹⁶. Numbers 333 represent the mutations ON target for each dataset. B) Comparison of immune dN/dS values using 334 SOPRANO SSB-192 and normalized HBMR values reported in Van Den Eynden et al.¹⁶ C) Linear regression 335 models for immune dN/dS and HBMR values versus median CD 8 T cell infiltration levels. In the analysis 336 with no MSI-rich tumors, in addition to colorectal (CRC), we removed Stomach and Uterine cancer (STAD 337 and UCEC). D) Linear mixed model using dN/dS values as the dependent variables and all immune metrics 338 as independent variables. Model selection using AIC revealed that ON/OFF dN/dS is strongly associated to 339 the levels of CD8 T cells. No immune value was associated to the global dN/dS (OFF).

340

341 To determine whether immune-mediated negative selection was associated with levels of immune activity, we compared immune dN/dS to the levels of immune 342 infiltration previously reported in TCGA data⁵¹ (Fig 3C). Median CD8 T cells 343 significantly correlated to the SOPRANO-derived immune dN/dS values in HLA-344 A0201 regions (p=0.0046) but not to the HBMR values (proto-HLA) calculated in 345 ¹⁶ (p=0.22), even though the trend was negative for both. As expected, the 346 347 correlation was also not observed in the simulated dataset. Interestingly, when tumour types where microsatellite instability (MSI) and mismatch-repair 348 deficiency was common, such as colorectal (CRC), stomach (STAD) and uterine 349 350 cancer (UCEC), were excluded from the analysis, the correlation between protoHLA HBMR and the median CD8 T cells was significant (P=0.028), indicating that negative selection acts differently in these different tumour subgroups. This makes sense as hypermutant MSI tumours have a large frequency of escape events, such as upregulation of immune checkpoint mechanisms, loss of heterozygosity in the HLA region or mutations in genes associated to the antigen presenting machinery^{28,33,52}. This last correlation was also strongly significant for cytolytic activity (P-value = 6e-04, Fig S6).

358

359 We applied a linear mixed model to determine the contribution to the global dN/dS360 (OFF), the immunopeptidome-specific (ON) and the immune-dN/dS (ON/OFF) 361 using reported immune variables (Fig 3D). We performed a stepwise model 362 selection, and the initial (Fig S7) and best performing model for predicting 363 Immune dN/dS (R-square adj= 0.89, AIC= -83, p-value = 0.01) had CD8 T cells 364 as the most significant explanatory variable. Importantly, none of the variables could explain global dN/dS values and seven out of the ten variables tested was 365 366 significantly associated to the immunopeptidome-specific ON value. Moreover, 367 we found that there was no significant correlation between CD8 T cells and 368 immune *dN/dS* in patients that have a truncating mutation in a gene associated to the antigen presenting machinery or genes defined as escape genes 369 370 previously³⁴.

371

In summary, these results highlight the importance of considering multiple confounding factors when drawing conclusions about the absence of negative selection at the cohort level using dN/dS. These results further suggest that high mutation burden tumors show signals of relaxed immune-selection confounding the calculation and interpretation of dN/dS probably due to the presence of acquired escape mechanisms, as our theoretical model predicts.


378

379 Immune-escaped tumors show relaxed immune-mediated negative
380 selection and high tumor immunogenicity

Following our immunoediting model, we hypothesized that escape events mask the signal of immune mediated negative selection and restore tumor immunogenicity. We ran SOPRANO using a patient specific immunopeptidome
(private HLA alleles) in colorectal (CRC), stomach (STAD) and uterine cancers
(UCEC). While tumor mutation burden was expectedly higher for MSI and POLE
tumors⁵³ (Fig S8), ON-target immunopeptidome *dN/dS* values for MSI and POLE
subtypes were also higher than for MSS tumors (Fig S9), consistent with highmutation rate tumours being very frequently immune-escaped²⁸.

389

390 We then classified different escape mechanisms for these tumors based on 391 previous work²⁸. We found that immune-escaped (Escape+) tumors have 392 significantly more somatic mutations compared to non-escaped (immune adapted) tumors (MSS p=0.0085 and MSI p=0.00026, Fig 4A). We then reasoned 393 394 that a larger number of mutations in MSS escape+ tumors would push immune 395 dN/dS towards 1, given an extended time of neutral mutations accumulating in 396 the genome *after* immune escape has occurred. Indeed, we found a significant positive correlation between tumor mutation burden and immune dN/dS for MSS 397 398 escape+ tumors but not for immune adapted tumors (Escape-, p=1e-04, Fig 4B), 399 suggesting that immune selection was still active in patients without an escape 400 mechanism. We observed the same results when restricting our analysis to only 401 clonal mutations (P Value = 0.003, Fig S10), confirming our previous suggestion 402 that immune-escape tends to occur early in the genesis of these malignancies²⁸.



403

404 Figure 4. Patient specific analysis of colorectal (CRC), stomach (STAD) and uterine cancer (UCEC) using 405 immune dN/dS. A) Tumor mutation burden (TMB) for different subtypes of cancers, including Microsatellite 406 Stable (MSS), Microsatellite Instable (MSI) and POLE mutants, classified as immune-adapted (-) or immune-407 escaped (+) based on the presence of escape mechanisms (obtained from Lakatos et al²⁸). B) Relationship 408 between Immune dN/dS values to TMB, following the same classification for patients as in A. C) Comparison 409 between immune dN/dS values for immune-escaped and immune-adapted MSS tumors using all or only 410 clonal mutations. D) Relationship between immune dN/dS values and the reported CD 8 T cell infiltration 411 following the same classification for patients as in A and B.

412

Our theoretical model predicted that immune dN/dS will remain lower than one 413 414 when at large clone sizes in non-escaped patients. We expected that clonal mutations may still hold the signature of negative selection (active before escape) 415 416 while subclonal mutations would be freely accumulating in immune-escaped 417 tumors. Consequently, when we compared immune dN/dS between immuneadapted (escape-) and immune-escaped (escape+) MSS tumors, we observed 418 that immune-escaped tumors had immune dN/dS values significantly closer to 1 419 420 compared to immune-adapted tumors when using all mutations, but not when using clonal mutations (0.88 versus 0.7, Wilcoxon signed rank test=0.0009, Fig 421

422 4C). In the case of immune-adapted tumors, the Immune dN/dS when using all 423 or clonal mutations remained similar (0.68 versus 0.70 immune dN/dS) while 424 immune-escaped tumors had a significantly higher immune dN/dS when using all 425 mutations (0.88 versus 0.66 immune dN/dS, P Value=0.007) (Fig S11).

426


427 To validate that the strength of immune-mediated negative selection depends on 428 immune activity, we compared the patient specific immune dN/dS to the CD8 T 429 cell infiltration (Fig 4D). We found a significant association between immune 430 activity and CD8 T cells in immune-adapted MSS tumors (P Value = 0.018), 431 reaffirming that native HLA binding regions hold information on the strength of 432 immune selection elicited by CD 8 T cells. Interestingly, MSI tumors without an 433 annotated escape mechanism did not follow this pattern suggesting that these 434 tumors may have an unknown escape mechanism. These results highlight the 435 importance of understanding the evolutionary dynamics of tumors under immunoediting and provide a theoretical explanation of why tumors with high 436 437 mutation burden are better candidates for immunotherapy. Such tumors have an 438 overall higher tumor immunogenicity that can be quantified using dN/dS in the 439 immunopeptidome.

440

Immune-escaped tumors have better response to immunotherapy thanimmune-adapted tumors

To finally address the clinical importance of escape mutations and immune dN/dS443 444 as a surrogate of tumor immunogenicity, we analysed 308 metastatic cases 445 subjected to immunotherapy with checkpoint inhibitors mainly with Ipilimumab, Nivolumab, Ipi+Nivo, and Pembrolizumab from the Hartwig Medical Foundation 446 447 cohort⁴ (Fig 5A). The specimens were sequenced before treatment was started. 448 Following RECIST guidelines patients were classified into complete and partial 449 response and into progressive or stable disease (Methods). There were 78 450 responders recorded (Partial or complete response) and 229 non-responders 451 (Progressive or Stable disease). Due to the unavailability of patient specific HLA, we calculated immune dN/dS using HLA-A0201 and observed a lower immune 452 *dN/dS* for non-responders compared to responders, suggesting that patients with 453

no response to immunotherapy were already adapted to the action of immune 454 response (Fig 5B). Next, we assembled a list of escape genes associated to the 455 456 immune response and further classified patients into immune-escaped and non-457 escaped (Methods). Given that only genomic data was available for this cohort, we could only classify patients into genetic escape and not into other immune 458 459 evasion events, such as overexpression of immune checkpoint inhibitors. We 460 found that the proportion of responders with a genetic escape mechanism was significantly higher compared to non-responders (Chi-square P value = 0.001, 461 462 Fig 5C), indicating that escape mechanisms were independently associated to 463 the clinical response during immune checkpoint therapy.



464

465 Figure 5. Analysis of Hartwig Medical Foundation metastatic cohort under immunotherapy. A) 308 patients 466 with information about their response post-immunotherapy were selected. B) Immune dN/dS values for 467 responders and non-responders reveals immune dN/dS lower than one for non-responders consistent with 468 an overall tumor immunogenicity unresponsive to immunotherapies. C) Proportion of escaped and non-469 escaped tumors classified by clinical response. Responders are enriched in genetic escape mechanisms. 470 D) Tumor mutation burden (TMB) for escaped and non-escaped tumors classified by response status. 471 Among non-escaped patients, responders have a higher TMB than non-responders. E) dN/dS values for driver genes (196 genes from Martincorena et al 7), escape genes, all the exome and for the 472 473 immunopeptidome. The panel show positive selection in driver genes for escaped tumors but not for non-474 escaped tumors. dN/dS in escape genes was indicative of positive selection for escaped tumors. Non-475 escaped tumors were selected for not having non-synonymous mutations in escape genes, hence dN/dS 476 was 0. Global dN/dS values were one for all cases consistent with the lack of selection in the majority of the 477 coding genome. dN/dS in the immunopeptidome was indicative of immune-selection for all groups except 478 for escaped tumors in responders.

479 Given that tumor mutation burden (TMB) is the current FDA-approved prognostic marker of immunotherapy, we compared TMB between responders and non-480 responders. As expected, we found that responders had a significantly higher 481 TMB than non-responders before the treatment (Fig S12A, P-value = 9.8*e-6, U 482 483 Mann Whitney). In parallel, we looked at TMB between escape and non-escaped 484 patients and found that escaped patients had also a significantly higher TMB 485 compared to non-escaped (Fig S12B, P-Value < 2.2e-16, U Mann Whitney). We 486 also explored if TMB was different within escaped and non-escaped groups 487 separated by response. We found that TMB was significantly higher for 488 responders among the non-escaped group (P Value=0.0054, U Mann Whitney) 489 but not different among escaped patients (P value=0.14, U Mann Whitney) (Fig 490 5D). The fact that, among non-escaped patients, responders had higher TMB. 491 suggest that a group of responders had an escape mechanism that was not 492 considered in our classification. This is expected given that we did not consider all possible escape mechanisms such loss of HLA heterozigosity³³, epigenetic 493 494 escape such as transcriptional silencing by changes in methylation³⁴, or extrinsic 495 factors such as the accumulation of dysfunctional T cells⁵⁴, all mechanisms of 496 immune evasion recently described in the literature.

497

498 Finally, we calculated *dN/dS* for driver, global, escape, and immune regions in 499 these four groups (Fig 5E). We found that the driver dN/dS was positive for non-500 escaped tumors as expectedly, but surprisingly neutral for immune-escaped 501 tumors. The escape dN/dS showed signals of positive selection for escaped 502 patients and given that no nonsynonymous escape mutations were present in non-escaped patients, the escape dN/dS was zero. The global dN/dS was 503 504 consistently close to one for all groups. Importantly, among escaped patients, 505 while the TMB was not different between responders and non-responders (Fig 506 5D), the immune dN/dS of non-responders was lower than one and lower than the immune dN/dS of responders. Ultimately, this validates immune-adaptation 507 508 in non-responders showing less neoantigens and therefore low levels of tumour immunogenicity for immunotherapies to have an effect. 509

510

511 Overall, our results highlight the importance of properly stratifying patients based 512 on escape mechanisms and immune dN/dS for a correct interpretation of the 513 evolutionary dynamics of tumors. In the future, these genomic based 514 classification in combination with current standard practices, could be used as 515 prognostic biomarkers for checkpoint inhibitor immunotherapies⁵⁵.

516

517 Discussion

518 The remarkable clinical response demonstrated by immune checkpoint inhibitors 519 (ICIs) has led to a growing interest in understanding the interactions between 520 cancer and immune cells^{33,35,56–58}. Although immunoediting is widely recognized 521 as an evolutionary process that selects for clones with low immunogenicity or 522 clones with an escape mechanism, its dynamics in the context of carcinogenesis 523 and response to treatment are poorly understood. During immunoediting, growing 524 cells are subjected to immune-mediated negative selection, shaping the landscape of mutations observed in cancer. However, negative selection in 525 cancer has been a controversial topic^{10,15,16}. While some studies have shown 526 527 evidence of an association between immune activity and selective pressures^{8,34,51,56,59}, others have claimed that there is a lack of evidence to prove 528 529 this relationship¹⁶. Given that several studies have applied dN/dS as a metric of selection in cancer and in normal tissue^{7,8,60-63}, we aimed to prove the use of 530 531 dN/dS in the immunopeptidome as a proxy of tumor immunogenicity and as a potential biomarker of immunotherapeutic response. In brief, we show that 532 533 immune dN/dS guantifies the extent of negative selection exerted by the immune 534 system and how levels of tumor immunogenicity measured by immune dN/dS can be used as a genomic biomarker for response to immunotherapy. 535

536

We first show the evolutionary dynamics of tumorigenesis under two radically different outcomes of immunoediting, immune-adaptation and immune-escape. Such distinction is a key feature of cancer evolution and has profound clinical implications. Immune-adapted tumors can only emerge in tissues where the immune system can exert a selective pressure, suggesting that tissues with a high capacity of immune recognition (immune-competent) are more likely to 543 generate clones with a depletion of immunogenic mutations if the probability of escape is low (i.e. a low mutation rate). A lower number of neoantigens could 544 allow tumors to grow in both low and high immunogenic tissues, potentially 545 making them more aggressive when colonizing new niches. Supporting our 546 547 hypothesis, a recent study of longitudinal recurrence of metastasis reported a 548 more aggressive phenotype in metastatic deposits that had higher levels of 549 immune-selection⁵⁶. However, whether tumor cells growing in immune-550 competent tissues are more likely to colonize new niches and how long it takes 551 those tumor cells to readapt or to find a novel escape mechanism, as has been previously observed in mice models^{29,31,50}, remains a challenging question. 552

553

554 Our immunoediting model predicts that immune-adapted tumours have an overall 555 low tumor immunogenicity and will be less likely to respond to ICIs regardless of tumor mutation burden status (TMB). TMB has been regarded as a measure of 556 tumor immunogenicity and is the current FDA-approved prognostic biomarker 557 558 used to enrol patients for ICI treatment. However, TMB does not capture the full 559 evolutionary history of the tumor and several patients do not respond despite their 560 TMB status. In addition, a recent study has shown that mismatch repair-proficient colorectal cancers can also achieve clinical response⁴⁴. Motivated by this, we 561 propose that immune dN/dS can be used, in addition to TMB and escape 562 563 mechanisms, to stratify patients into adapted and escaped. As evidence of this, 564 we demonstrate that in a metastatic cohort, non-responders have an immune dN/dS lower than one prior to immunotherapy and are thus immune-adapted, 565 whereas responders have immune dN/dS values of one, and are more likely to 566 567 be immune-escaped.

568

In conclusion, our study reflects the importance of understanding the evolutionary dynamics of immunoediting during tumor evolution and how immune selection edits the genome of tumor cells. Differentiating between immune adapted and immune escaped tumors is a key factor when predicting which patients will benefit from immunotherapies. In the future, we believe that immune dN/dS can be used as read-out of tumor immunogenicity, that, in combination with other prognostic

575 measurements, can be used to predict response to immunotherapy.

576

577 **References**

8			
	1.	Nowell, P. C. The clonal evolution of tumor cell populations. Science (80). 194, 23-28 (1976).	
	2.	Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012).	
0	3.	Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719–724 (2009).	
1 2	4.	Priestley, P. <i>et al.</i> Pan-cancer whole-genome analyses of metastatic solid tumours. <i>Nature</i> 575 , 210–216 (2019).	
3 1	5.	Martincorena, I. <i>et al.</i> Somatic mutant clones colonize the human esophagus with age. <i>Science (80).</i> 362 , 911–917 (2018).	
_	6.	Yokoyama, A. et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565,	
6	0.	312–317 (2019).	
7	7.	Martincorena, I., Raine, K. M., Davies, H., Stratton, M. R. & Campbell, P. J. Universal Patterns of Selection in	
3		Cancer and Somatic Tissues. <i>Cell</i> 171 , 1029-1041.e21 (2017).	
-	8.	Zapata, L. et al. Negative selection in tumor genome evolution acts on essential cellular functions and the	
0		immunopeptidome. <i>Genome Biol.</i> 19 , 67 (2018).	
	9.	Weghorn, D. & Sunyaev, S. Bayesian inference of negative and positive selection in human cancers. Nat	
2	0.	Genet 49, 1785–1788 (2017).	
_	10.	López, S. <i>et al.</i> Interplay between whole-genome doubling and the accumulation of deleterious alterations in	
4	10.	cancer evolution. <i>Nat. Genet.</i> 52 , 283–293 (2020).	
_	11.	Davis, A., Gao, R. & Navin, N. Tumor evolution: Linear, branching, neutral or punctuated? <i>Biochim. Biophys.</i>	
6		Acta - Rev. Cancer 1867 , 151–161 (2017).	
_	12.	Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. & Sottoriva, A. Identification of neutral tumor	
, 8	12.	evolution across cancer types. <i>Nat Genet</i> 48 , 238–244 (2016).	
-	13.	Heide, T. et al. Reply to 'Neutral tumor evolution?' Nat. Genet. 50, 1633–1637 (2018).	
0	14.	Tarabichi, M. <i>et al.</i> Neutral tumor evolution? <i>Nat. Genet.</i> 50 , 1630–1633 (2018).	
1	15.	Bakhoum, S. F. & Landau, D. A. Cancer Evolution: No Room for Negative Selection. <i>Cell</i> 171 , 987–989 (2017)	
-	16.	Van den Eynden, J., Jiménez-Sánchez, A., Miller, M. L. & Larsson, E. Lack of detectable neoantigen depletior	
3	10.	signals in the untreated cancer genome. <i>Nat. Genet.</i> 51 , 1741–1748 (2019).	
	17.		
_	17.	Nordling, C. O. A new theory on the cancer-inducing mechanism. <i>Br. J. Cancer</i> 7 , 68 (1953). Tomasetti, C., Marchionni, L., Nowak, M. A., Parmigiani, G. & Vogelstein, B. Only three driver gene mutations	
5	10.	are required for the development of lung and colorectal cancers. <i>Proc Natl Acad Sci U S A</i> 112 , 118–123	
7			
-	19.	(2015). Temko, D., Tomlinson, I. P. M., Severini, S., Schuster-Böckler, B. & Graham, T. A. The effects of mutational	
9	19.		
-	20.	processes and selection on driver mutations across cancer types. <i>Nat. Commun.</i> 9 , (2018).	
1	20.	Williams, M. J. <i>et al.</i> Quantification of subclonal selection in cancer from bulk sequencing data. <i>Nat. Genet.</i> 1–	
-	01	(2018). doi:10.1038/s41588-018-0128-6	
2 3	21.	Williams, M. J. <i>et al.</i> Measuring the distribution of fitness effects in somatic evolution by combining clonal	
		dynamics with dN/dS ratios. <i>Elife</i> 9:e48714 , 661264 (2020).	
4	22.	Watson, C. J. <i>et al.</i> The evolutionary dynamics and fitness landscape of clonal hematopoiesis. <i>Science (80).</i>	
5		367 , 1449–1454 (2020).	
	23.	McFarland, C. D., Korolev, K. S., Kryukov, G. V, Sunyaev, S. R. & Mirny, L. A. Impact of deleterious passenge	
7		mutations on cancer progression. Proc Natl Acad Sci U S A 110, 2910–2915 (2013).	
	24.	McFarland, C. D., Mirny, L. A. & Korolev, K. S. Tug-of-war between driver and passenger mutations in cancer	
)		and other adaptive processes. Proc Natl Acad Sci US A 111, 15138–15143 (2014).	

620	05	
620	25.	Van den Eynden, J. & Larsson, E. Mutational Signatures Are Critical for Proper Estimation of Purifying
621		Selection Pressures in Cancer Somatic Mutation Data When Using the dN/dS Metric. Front Genet 8, 74
622		(2017).
623	26.	Persi, E., Wolf, Y. I., Leiserson, M. D. M., Koonin, E. V & Ruppin, E. Criticality in tumor evolution and clinical
624		outcome. Proc. Natl. Acad. Sci. U. S. A. 115, E11101–E11110 (2018).
625	27.	Pyatnitskiy, M., Karpov, D., Poverennaya, E., Lisitsa, A. & Moshkovskii, S. Bringing Down Cancer Aircraft:
626		Searching for Essential Hypomutated Proteins in Skin Melanoma. PLoS One 10, e0142819 (2015).
627	28.	Lakatos, E. et al. Evolutionary dynamics of neoantigens in growing tumours. bioRxiv 536433 (2019).
628		doi:10.1101/536433
629	29.	Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from
630		immunosurveillance to tumor escape. Nature Immunology 3, 991-998 (2002).
631	30.	Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and
632		immunoediting. Immunity 21, 137–148 (2004).
633	31.	Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: Integrating immunity's roles in cancer
634		suppression and promotion. <i>Science (80).</i> 331 , 1565–1570 (2011).
635	32.	Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
636	02.	Nature 482, 400–404 (2012).
637	33.	McGranahan, N. <i>et al.</i> Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> 171 ,
638	00.	1259-1271.e11 (2017).
639	34.	Rosenthal, R. <i>et al.</i> Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> 567 , 479–485
640	54.	(2019).
641	05	
642	35.	Chowell, D. <i>et al.</i> Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.
642 643		Nat. Med. doi:10.1038/s41591-019-0639-4
	36.	Bräunlein, E. & Krackhardt, A. M. Identification and Characterization of Neoantigens As Well As Respective
644		Immune Responses in Cancer Patients. <i>Front. Immunol.</i> 8 , 1–8 (2017).
645	37.	Fritsch, E. F. et al. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol. Res. 2, 522–529
646		(2014).
647	38.	Charoentong, P. et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype
648		Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 18, 248–262 (2017).
649	39.	Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in
650		human cancer. Immunity 39 , 782–795 (2013).
651	40.	Galon, J. et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J
652		Pathol 232, 199–209 (2014).
653	41.	Quezada, S. A., Peggs, K. S., Simpson, T. R. & Allison, J. P. Shifting the equilibrium in cancer immunoediting:
654		From tumor tolerance to eradication. Immunol. Rev. 241, 104-118 (2011).
655	42.	Gajewski, T. F., Schreiber, H. & Fu, YX. Innate and adaptive immune cells in the tumor microenvironment.
656		Nat Immunol 14, 1014–1022 (2013).
657	43.	Dupage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens
658		underlies cancer immunoediting. Nature 482, 405–409 (2012).
659	44.	Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-
660		deficient early-stage colon cancers. Nat. Med. (2020). doi:10.1038/s41591-020-0805-8
661	45.	Durrett, R. Branching Process Models of Cancer Multistage theory of cancer. (Springer International
662		Publishing, 2015). doi:10.1007/978-3-319-16065-8_1
663	46.	Gatenbee, C. et al. Macrophage-mediated immunoediting drives ductal carcinoma evolution: Space is the
664		game changer. <i>bioRxiv</i> 594598 (2019). doi:10.1101/594598
665	47.	Williams, M. J., Sottoriva, A. & Graham, T. A. Measuring Clonal Evolution in Cancer with Genomics. Annu.
666	<i></i>	Rev. Genomics Hum. Genet. 20, (2019).
667	48.	Gejman, R. S. et al. Rejection of immunogenic tumor clones is limited by clonal fraction. Elife 7, 1–22 (2018).
007	-1 0.	Contact, r_1 , σ_2 , r_2 , r_3 , r_3 , r_2 , r_3 , r_4 ,

668	49.	Yang, Z. & Nielsen, R. Estimating synonymous and nonsynonympus substitution rates under realistic
669		evolutionary models. Mol Biol Evol 17, 32-43 (2000).
670	50.	Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907
671		(2007).
672	51.	Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors
673		associated with local immune cytolytic activity. Cell 160, 48-61 (2015).
674	52.	Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372, 2509–2520
675		(2015).
676	53.	Loupakis, F. et al. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic
677		Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist 25, 481-487 (2020).
678	54.	Ghorani, E. et al. The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nat.
679		<i>Cancer</i> 1 , 546–561 (2020).
680	55.	Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor
681		immunotherapy. Nat. Rev. Cancer 19, 133–150 (2019).
682	56.	Angelova, M. et al. Evolution of Metastases in Space and Time under Immune Selection. Cell 1–15 (2018).
683		doi:10.1016/j.cell.2018.09.018
684	57.	Zhang, A. W. et al. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell 173,
685		1755-1769.e22 (2018).
686	58.	AbdulJabbar, K. et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
687		<i>Nat. Med.</i> (2020). doi:10.1038/s41591-020-0900-x
688	59.	Zhang, A. W. et al. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell 1-15
689		(2018). doi:10.1016/j.cell.2018.03.073
690	60.	Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532-537
691		(2019).
692	61.	Muyas, F., Zapata, L., Guigó, R. & Ossowski, S. The rate and spectrum of mosaic mutations during
693		embryogenesis revealed by RNA sequencing of 49 tissues. Genome Med. 12, 1–19 (2020).
694	62.	Benvenuto, M. et al. Tumor antigens heterogeneity and immune response-targeting neoantigens in breast
695		cancer. Semin. Cancer Biol. 1-12 (2019). doi:10.1016/j.semcancer.2019.10.023
696	63.	Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in
697		metastatic breast cancer. Nat. Med. 24, 724-730 (2018).
698	64.	Caravagna, G. et al. Model-based tumor subclonal reconstruction. 1-31 (2019).
699	65.	Fay, M. P. Two-sided exact tests and matching confidence intervals for discrete data. R J. 2, 53-58 (2010).
700		

701 Acknowledgements

L.Z. is supported by the European Union's Horizon 2020 research and innovation 702 703 programme under the Marie Skłodowska-Curie Research Fellowship scheme 704 (846614). A.S. is supported by the Wellcome Trust (202778/B/16/Z) and Cancer Research UK (A22909). We acknowledge funding from the National Institute of 705 706 Health (NCI U54 CA217376) to A.S. and T.G. This work was also supported by a Wellcome Trust award to the Centre for Evolution and Cancer (105104/Z/14/Z). 707 708 We thank Claire-Alix Garin and Marco Punta for support and discussion. This 709 publication and the underlying study have been made possible partly on the basis

of the data that Hartwig Medical Foundation and the Center of Personalised
Cancer Treatment (CPCT) have made available to the study.

712

713 Author contributions

LZ conceived, designed, implemented and performed all analysis, GC supported with the model implementation, MW, EL, and BW provided support with the mathematical inferences of the model. KAJ provided bioinformatic support. TG and AS supervised the project. LZ wrote the first draft of the manuscript. LZ, AS and TG wrote the final version of the manuscript with the help of all the authors.

719

720 Competing interests

721 The authors declare no competing interests.

722

723 Data availability

TCGA data was obtained from GDC portal and processed as described in¹³. Assembled list of escape mechanisms for COAD, READ and STAD and UCEC was obtained from Lakatos et al²⁸. Hartwig Medical Foundation data was downloaded from Hartwig Data Portal. HBMR values of selection in the immunopeptidome were obtained from the supplementary material in Van Den Eynden et al¹⁶. Normalized scores for immune cell infiltration was obtained from Rooney et al⁵¹.

731

732 Code Availability

SOPRANO is freely available at github.com/luisgls/SOPRANO. Simulator of
stochastic branching process for immunoediting is available at
github.com/luisgls/dNdSSimulator upon request. All figures are available as a
markdown file.

737

738 Methods

739 **1.0 Evolutionary model of tumorigenesis under immunoediting**

740 **1.1 Computational model**

We have developed a discrete-time non-spatial stochastic branching process of somatic evolution. It models the acquisition of somatic mutations and their associated effect on the phenotype of single cells. The model can be initialized with any number of wild-type single cells and a set of initial parameters described in supplementary table 1A.

746

747 **1.2 Cell division process**

The model simulates cellular proliferation starting from x_0 identical initial cells available at time $t_0 = 0$, that divide synchronously; each time-step therefore is represented in units of tumour doublings or generations, as in earlier works⁴⁷.

751

At every time-step every single cell (SC) in the model undergoes a stochastic process with a probability that depends on a parameter p_i . The outcomes of this process are either zero, one, or two single cells in the model:

- 755
- 756 $SC \xrightarrow{p_2} SC + SC$
- 757 $SC \xrightarrow{p_1} SC + D$
- 758 $SC \xrightarrow{p_0} D + D$
- 759

760 where $p_0 + p_1 + p_2 = 1$ and D denotes "dead" cells. We consider death as any 761 process that removes the cell from the dividing population, such as apoptosis, 762 senescence, quiescence, or differentiation. To simplify the possible outcomes of the model, we consider $p_1 = 0$. Thus, our branching process consists only of no 763 division (no offspring) or a successful cell division (two daughter cells), that is 764 765 $p_0 + p_2 = 1$. Given that $p_0 = 1 - p_2$, we can define the probability of survival 766 $p_2 = \Delta$ as the parameter of fitness for each single cell. In the case of a neutral 767 branching process and at the initial state of the simulation (time t_0) the probability 768 of cell division is equal to the probability of cell death/differentiation for each single 769 cell ($\Delta = 0.5$).

770

We can translate this parameter Δ into a birth death process with $b/d = \omega$ using:

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.21.215038; this version posted July 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

773	$\omega = 2 * p2 + 1 * p1 + 0 * p0$	
774	$\omega = 2 * \Delta$	
775	[2]	
776	$\omega = b/d$	
777	$b/d = 2 * \Delta$	
778		
779	when $\Delta = 0.5$ the birth death ratio $b/d = 1$.	
780		
781	The population grow exponentially when the probability of division (Δ) is 1. The	
782	probability of survival Δ used as a phenotype allow us to define a driver clone. A	
783	driver clone is a set of cells from the same evolutionary lineage which have the	
784	same Δ across them. This implies that they all have a shared set of mutations	
785	(very few or all) and the same survival probability. We also define an	
786	immunogenic clone, defined by the presence of an ancestral cell that acquired at	
787	least one immunogenic mutation.	
788		
789	1.3 Cell genotypes and phenotypes.	
790		
791	The genotype of each single cell is implemented as a vector storing the following	
792	information:	
793		
794	• Number of nonsynonymous mutations in driver, immune, escape, and	
795	passenger regions of the coding genome.	
796	• Number of synonymous mutations in driver, immune and passenger	
797	regions of the coding genome.	
798		
799	At every successful cell division, each cell inherits the genotype from the parental	
800	cell, which is further modified by acquiring a new set of mutations. The number	
801	of new mutations is given by a Poisson distribution with mean $u * L$ with $L = 50 *$	
802	10^6 , u is the mutation rate per bp per cell division, and L is the length of the	
803	coding genome.	

804

805 The phenotype of each single cell is implemented as a vector storing the following

806 information:

807

Fitness (probability of successful cell division) and strategy (passenger,
 driver, immunogenic or escape),

810

These phenotypes are the outcome of mutations present in the genotype vector. To estimate the target size and thus the vector of probabilities for passenger, driver, immunogenic, and escape mutations we used prior information and also explored different values. All tested values are described in supplementary table 1B.

816

817 **1.4 Cycle conditions**

818 Our model requires the input of several parameters described in supplementary 819 Table 1. We performed several simulations to account for the different phases 820 described in figure 1. The parameters for the simulations are described in 821 supplementary table 1B.

822

823 Mutation rate

Specifically, for MSS cases, we used a mutation rate per pb per cell division of 10⁻⁸. This value is a composite between the polymerase error and the DNA proofreading correction efficiency. For MSI and POLE cases we increased this value in one and two orders of magnitude respectively.

828

829 Initially, we estimated the probability of hitting a driver mutation (1%) based on 830 the number of driver genes identified in a recent study using a pancancer dataset (~200 out of 20000 genes)⁷. We used 5% of the coding genome as immunogenic 831 based on our recent analysis of immunogenic mutations²⁸ and based on the 832 833 length of all possible 9-mers defined as strong binders by NetMHCpan. The 834 proportion of escape sites in the coding genome is unknown, thus we simulated 835 different proportions ranging from 0.01% to 5%. In addition, we defined 836 nonsynonymous mutations as: a) passenger mutations that do not have any

837 effect on the phenotype, b) driver mutations increasing the probability of survival, 838 c) immunogenic mutations that may elicit an immune response, d) escape mutations allowing the cell to hide from an immune attack. We assume that all 839 synonymous mutations accumulate neutrally in the genome and define three 840 841 types of synonymous a) synonymous mutations in neutral regions, b) in driver 842 regions, and c) in the immunopeptidome. To simulate the dependency of the 843 nonsynonymous to synonymous mutation ratio, dN/dS values, for global, driver 844 and immune regions, we fixed the probability of synonymous mutations as 1/3 of 845 the probability of the nonsynonymous mutations in the same locus. All these 846 probabilities sum to one.

847

Then, each time a cell divides, each daughter cell inherits the parental genotype 848 849 and an additional set of nonsynonymous and synonymous mutations based on 850 the probability vector defined. Our model assumes infinite-sites and no -back mutation as used in previous studies⁶⁴. Our model records the number of 851 852 mutations for each mutation type, the probability vector for each of those 853 mutations, the probability of survival and the probability of immune attack over 854 time. We also store the parental relationship and we assign a new clone id only when the new genotype includes nonsynonymous driver different from the 855 856 parental phenotype.

857

We stopped the simulation after 100 generations, consistent with the maximum number of cell divisions allowed by telomere shrinking, or when the population size reached a specific carrying capacity (2000 cells).

861

862 **1.4 Mutation effects**

863 **Phenotype 1 - Proliferation dynamics**

We have developed a flexible framework to account for different models of fitness effects of driver mutations. We chose a model based on that to date we have mostly seen tumors having between 2-10 drivers, therefore at equilibrium we expect to reach an average of 5 clones each carrying a driver event or 1 clone carrying 5 driver events. Thus, we modelled the fitness increase by a driver event

869 as a Gompertz function where driver events give different selective advantages 870 based on the order of acquisition given by: 871 $S(d) = 0.5 * e^{-b*e^{-cd}}$ 872 873 874 where b defines the displacement scale parameter of the Gompertz function, c defines the scale parameter on the fitness effect for each driver, and d is the 875 876 number of driver events. We sample b from a normal distribution with mean 5 and c has a fixed value of 1. 877 878 879 Finally, at each time point each cell has a probability of survival defined by: 880 $\Delta = 0.5 + S(d)$ 881 882 883 We must emphasize that the choice on these functions is perhaps one of the 884 most important open questions in the field of cancer evolution. The fitness effects 885 of combinations of multiple drivers (epistasis), the proportion of mutated sites 886 leading to an increase/decrease of a selective advantage, and whether there is an upper boundary for the fitness increase remain largely unsolved and it was 887 888 not the scope of this work. Here, we aimed to explore the effects of the immune 889 system, the selective pressures and the emergence of escape mutations on a 890 single unifying framework of tumor evolution. 891 892 Phenotype 2 - Immunoediting: 893 To model the effect of the immune system during somatic evolution we assume 894 two possible scenarios.

895

In the first, we allow cells to accumulate immunogenic mutations based on the size of the immunogenic genome and the mutation rate. Each immunogenic mutation will be detected by the immune system at an immune-mediated cell death rate of P_{IS} that will remove the immunogenic cell. This rate can be seen as the healthiness of the immune system or the capacity of T-cell recognition based 901 on the diversity of the TCR repertoire (with 0 for immunosuppressed to 1 for 902 immunocompetent, alternatively this can be seen as low recognition or high 903 recognition potential by TCRs). By simplifying this value to an external probability 904 independent of the genome, it allows us to model the effect of the 905 microenvironment.

906

In the second, we define a function that at every generation calculates how many cells in a given clone are immunogenic (at least one neoantigen) and if this number is greater than a selected cut-off value (50 cells in our model), we kill all cells from that clone given a certain probability (defined previously as P_{IS}). An immunogenic cell carries at least one immunogenic mutation and have not acquired an escape mutation. When a cell acquires an escape mutation, the immune system will no longer attack this cell.

914

915 1.5 dN/dS computation

To estimate the dN/dS ratio we fixed the initial probabilities of occurrence of nonsynonymous mutations to be three times higher than the occurrence of synonymous mutations, as naturally observed in the coding portion of the human genome.

920

In general, in the first cellular divisions the number of synonymous mutations is
close to 0 for many cells making the calculation of dN/dS implausible (infinite).
We calculated the dN/dS for all mutations (global dN/dS), driver mutations (driver
dN/dS) and immunogenic mutations (immune dN/dS) by adding up the observed
counts in the alive cells at a given time t.

926

dN	$\sum ns_passenger + \sum ns_driver + \sum ns_immunogenic + \sum ns_escape$
alohal	$= \frac{\sum ns_passenger + \sum ns_earriver + \sum ns_earriver + \sum s_escape}{3 * (\sum s_passenger + \sum s_driver + \sum s_escape)}$

928

927

929

 $driver \ \frac{dN}{dS} = \frac{\sum ns_driver}{3 \ * \ \sum s_driver}$

931 $Immune \ \frac{dN}{dS} = \frac{\sum ns_{immunogenic}}{3 \ * \ \Sigma \ s_{immunogenic}}$

932

933 1.6 Frequency dN/dS

To estimate the dN/dS ratio using a specific mutation frequency cut off we 934 simulated sequencing by giving a mutation ID to each new mutation acquired 935 936 during the stochastic branching process. We determine the cell-specific mutation 937 by implementing an algorithm that walks along the lineage of a cell and concatenate all inherited mutations. We build a matrix of all alive cells and 938 939 mutations at the last time point. We then were able to filter out variants present in less than any predefined threshold. For the driver section we used 0.01%, 1%, 940 941 2%, 3%, 4%, 5%, 10%, 25%, and 50% as frequency cut-offs. For the immune 942 section we used 0.1%, 1%, 5%, 10% and 50% as frequency cut-offs. To estimate 943 dN and dS we assigned each inherited mutation a unique id. Given that each 944 mutation has two labels, a first label defined as 1) nonsynonymous and 945 synonymous, and a second label defined as a 2) passenger, driver and 946 immunogenic. This allowed us to calculate a global, driver, and immune dN/dS accordingly. Then, each simulation consisted of N number of cells with a specific 947 948 number of nonsynonymous and synonymous driver, immunogenic, and 949 passenger mutations.

950

951 **1.7 dN/dS confidence Intervals for frequency or cancer cell fraction cut-offs**

When performing the analysis using frequency cut-offs, we pulled simulations together similar to what is done in cohort studies when all nonsynonymous and synonymous mutations are pulled together. To estimate the confidence interval for this analysis, we used the rateratio.test function from R package rateratio. This function calculates the p-value and the confidence interval for the rate of two Poisson ratios. It uses the uniformly most powerful ratio test available for R⁶⁵.

958

959 **2.0 TCGA Data**

We first obtained somatic calls of TCGA data from GDC. This dataset consisted of 10202 samples across 33 tumors types. We then selected 19 tumor types tumor types that had been analysed in Rooney et al⁵¹ in order to compare our results of immune dN/dS to the immune cell scores. Rooney et al provided the per patient values of several normalized scores for immune cells. We calculated the median value for each score within each tumor type. The final list analysed consisted of 8543 samples across 19 tumor types. TCGA data was then reannotated using ensembl-VEP release 89. COAD (Colon adenocarcinoma) and READ (Rectum Adenocarcinoma) were merged into CRC.

969

HLA-binding Mutation Ratios (HBMR) and simulated HBMRs were obtained from
the supplementary material in Van Den Eynden et al¹⁶ available for 19 tumor
types. Hartwig somatic calls and metadata were obtained from Hartwig Medical
Foundation under license agreement DR-075.

974

975 2.1 Selection On PRotein ANotated regiOns, SOPRANO

976 SOPRANO was developed on top of the method developed in Zapata et al 2018 977 to calculate selection in VEP annotated files and is freely available in github.com/luisgls/SOPRANO. It estimates dN/dS values in a target region (ON-978 target) and in the rest of the proteome (OFF-target) using a trinucleotide context 979 correction (SSB192) or a 7-nucleotide context (SSB7). It allows the option to 980 981 include or exclude cancer driver genes, as well as, randomizing the target region 982 to calculate a background distribution of a matching size region. Given that it uses a set of Ensembl transcript identifiers and their respective FASTA file it allows 983 984 calculation of dN/dS in any genome irrespective of the version. We ran 985 SOPRANO on 33 tumor types and deposited the results for each tumor type in 986 Synapse (syn22149238).

987

988 2.2 Immunopeptidome and patient specific HLA

We downloaded a set of protein coding transcripts with HGNC symbol from Ensembl Biomart. We obtained all transcript lengths and run bedtools makewindows to get all possible overlapping 9-mers. We then obtained the FASTA sequence for each of all 9-mer and run netMHCpan4 using a list of HLAalleles. This list of HLA-alleles was restricted to those that have more than 1% population frequency in a list of 1277 samples from the 1000K cohort. We selected all possible strong binders which had a mean and a median expression above 1FPKM. We obtained expression values for different tissues from thehuman protein atlas (downloaded on 05/10/2018).

998

3.0 Analysis of Metastatic cohort pre-immunotherapy from Hartwig Medical Foundation

1001

1002 We obtained the somatic mutation data from the Hartwig Medical Foundation 1003 cohort (HMF) under license agreement DR-075. The data we used for this 1004 manuscript consisted on 308 metastatic patients that underwent immunotherapy post-biopsy and that had recorded clinical response in "first response" column 1005 from the metadata. Mutation types that were not classified as synonymous, 1006 missense, start lost, stop gained, stop lost or frameshift mutation were excluded. 1007 1008 We removed indels and reannotated SNVs following our pipeline to obtain high 1009 confidence calls for a predefined set of ensemble transcripts (~20000 genes). We then rerun ensemble VEP using version 90 for Grch37 and parse the file using 1010 1011 VATools V1.0.0. We uploaded the final annotated file used for the rest of the 1012 manuscript for each of the 308 patients to Synapse.

1013

It is important to note that the raw clinical data was supplied by HMF and final 1014 consistency checks are still to be performed. The response evaluations were not 1015 1016 performed as part of a clinical trial and the timing of the evaluations was variable. 1017 We classified patients into responders and non-responders based on the first response recorded after treatment was initiated. The group of responders 1018 1019 consisted of those that were labelled complete response (CR, 1 case), or partial 1020 response (PR, 78 cases). Those that were labelled stable diseases (SD, 98 1021 cases) or progressive disease (PD, 131 cases) were classified as non-1022 responders. To keep consistency with other studies, there were 79 cases with no 1023 data, two cases classified as clinical progression, four cases classified as ND, 1024 and 3 cases classified as Non-CR/Non-PD which were not included in the 1025 analysis. The timing from biopsy to response was not included. There were no other further classifications performed. 1026

1027


Escape genes were selected based on the list of Antigen Processing and Presentation Machinery (hsa04612) download from KEGG. In addition, we included escape genes used in Rosenthal et al³⁴. We then classified responders and non-responders into "escaped" if there was a missense or a truncating mutation in one of these escape genes and into "adapted" otherwise.


1033

All statistical tests were performed using R statistical language. Statistical tests were performed using Wilcoxon rank-sum test for two distributions or Kruskal-Willis test when more than two distributions were present using the R package ggstatsplot.

1038

We ran SSB192 (github.com/luisgls/SSB-dNdS) with default parameters to 1039 1040 determine and global dN/dS values and SOPRANO gene 1041 (github.com/luisgls/SOPRANO) using the bed file provided in the package for HLA-A0201 using 192-base pair correction. We calculated dN/dS for driver genes 1042 using the list of 196 genes provided in Martincorena et al⁷. We calculated SSB-1043 1044 dNdS and immune dN/dS in the four group categories. For the TCGA patient 1045 specific SOPRANO analysis we used the 4-digit code HLA type for each gene (HLA-A, HLA-B, and HLA-C). We concatenated all regions predicted to bind to 1046 netMHCpan4.0 as strong binders in those genes that have a median expression 1047 of more than 1FPKM calculated across the 33 TCGA cancer types. 1048





Immune Adapted/ Low immunogenicity

Immune Escaped/ Low-High immuno-genicity

~ 1		
>1		
<1	Adapted	
~ 1	Escaped	

